Skip to main content
Top
Published in: Journal of Hematology & Oncology 1/2018

Open Access 01-12-2018 | Correction

Correction to: Role of protein kinases CK1α and CK2 in multiple myeloma: regulation of pivotal survival and stress-managing pathways

Authors: Sabrina Manni, Marilena Carrino, Francesco Piazza

Published in: Journal of Hematology & Oncology | Issue 1/2018

Login to get access

Excerpt

The original article [1] contains an inadvertent error in the following sentence in the Abstract regarding the erroneous description of Ser/Thr kinases as ‘phylogenetically related’:
‘The phylogenetically related Ser/Thr kinases CSNK1A1 (CK1α) and CSNK2 (CK2) have recently gained a growing importance in hematologic malignancies arising both from precursors and from mature blood cells.’
The authors would like to note that the aforementioned Ser/Thr kinases are instead distantly related and that consequently, the sentence should read as the following instead:
‘The distantly related Ser/Thr kinases CSNK1A1 (CK1α) and CSNK2 (CK2) have recently gained a growing importance in hematologic malignancies arising both from precursors and from mature blood cells.’
Literature
1.
go back to reference Manni S, et al. Role of protein kinases CK1α and CK2 in multiple myeloma: regulation of pivotal survival and stress-managing pathways. J Hematol Oncol. 2017;10:157.CrossRefPubMedPubMedCentral Manni S, et al. Role of protein kinases CK1α and CK2 in multiple myeloma: regulation of pivotal survival and stress-managing pathways. J Hematol Oncol. 2017;10:157.CrossRefPubMedPubMedCentral
Metadata
Title
Correction to: Role of protein kinases CK1α and CK2 in multiple myeloma: regulation of pivotal survival and stress-managing pathways
Authors
Sabrina Manni
Marilena Carrino
Francesco Piazza
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2018
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/s13045-018-0588-2

Other articles of this Issue 1/2018

Journal of Hematology & Oncology 1/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine